Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
Fifty-seven patients with a diagnosis of schizophrenia were started on either fluphenazine decanoate or flupenthixol decanoate injections in a double-blind trial just prior to discharge into the community. During the six month follow-up 30 per cent dropped out of the treatment. Of those observed for six months, 7 per cent relapsed, 54 per cent experienced depressive symptoms and 88 per cent extrapyramidial side-effects. Analysis of both clinical data and the ratings failed to discriminate between the two drugs.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced*; D005475:Flupenthixol / Q000009:adverse effects / Q000627:therapeutic use*; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012917:Social Adjustment; D013892:Thioxanthenes / Q000627:therapeutic use*
D013892:Thioxanthenes; D005475:Flupenthixol; D005476:Fluphenazine